TG Therapeutics Ranked Number 5 on 2026 Deloitte Technology Fast 500
TG Therapeutics, Inc. has been recognized as the fifth fastest-growing company in North America on the 2026 Deloitte Technology Fast 500 list.
Stocks · News reference
TG Therapeutics announced its financial results for the third quarter of 2026, reporting revenue of $259.9 million and raising its full-year revenue guidance.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
TG Therapeutics, Inc. has been recognized as the fifth fastest-growing company in North America on the 2026 Deloitte Technology Fast 500 list.
TG Therapeutics has been recognized as one of the top five small employers in the biopharmaceutical industry in BioSpace's 2027 Best Places to Work list.
Biotech ETFs face key FDA catalysts as Summit Therapeutics' decision and the Hims-Lilly GLP-1 deal put XLV, IBB and XBI in focus.
TG Therapeutics (NASDAQ:TGTX) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs.